The effects of statins with a high hepatoselectivity rank on the extra-hepatic tissues; New functions for statins.
Level 5 - mechanism / opinion, no new human data
Narrative review detailing theoretical and biochemical mechanisms without new primary data
PubMed 31891788 · doi:10.1016/j.phrs.2019.104621
What was done
This review synthesized literature on the biological and pleiotropic effects of statins, focusing specifically on the physiological consequences in extra-hepatic tissues when using statin formulations engineered for high hepatoselectivity.
What was found
The abstract presents a qualitative mechanistic overview without quantitative data. It reports that statin-induced inhibition of hepatic cholesterol synthesis lowers whole-body cholesterol, prompting extra-hepatic tissues to upregulate endogenous cholesterol synthesis when statins lack direct access to these peripheral organs. The consequences of restricted extra-hepatic tissue drug access on non-hepatic biological pathways were evaluated.
Why it matters
Understanding how hepatoselective statins alter peripheral tissue homeostasis helps clarify whether minimizing non-hepatic drug exposure truly avoids off-target effects or merely shifts peripheral cell biology through secondary systemic metabolic changes.
Limits
The abstract reports no empirical data, meta-analytic metrics, sample sizes, or systematic review methodology. It relies on narrative and mechanistic reasoning, and clinical outcomes or adverse event rates in human populations are not quantified.
Cited by
- supports The liver produces approximately 80% of circulating cholesterol in the human body.